AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, where epcoritamab combined with lenalidomide significantly improved progression-free survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial showed a 60% reduction in risk of disease progression or death compared to standard chemoimmunotherapy. This chemotherapy-free regimen offers a promising new treatment option for difficult-to-treat DLBCL cases. AbbVie and Genmab plan to engage regulators and present data at future medical meetings.
A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due dilige...
US equity markets show signs of speculative excess with record margin debt at $1.4 trillion and leveraged ETF assets at $198 billion. The tech-heavy Nasdaq experienced its largest weekly drop since April 2025, reflecting a pullback in the most specul...
A new study analyzing nearly 68,000 US patients found that adoption of adalimumab biosimilars increased significantly after formulary changes, but over 16% of those who switched from Humira reverted back to the original drug. The research highlights ...
The European Medicines Agency's CHMP has given a positive opinion recommending approval of AbbVie's upadacitinib for treating severe alopecia areata in adults and adolescents. This recommendation follows Phase 3 trial data showing significant hair re...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending upadacitinib for treating adult and adolescent patients with non-segmental vitiligo, a chronic autoimmune skin disease. Th...
